Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
N2OFF ( (NITO) ) has issued an announcement.
On October 20, 2025, N2OFF completed the acquisition of MitoCareX Bio Ltd., a biotech firm specializing in drug discovery for resistant cancers, including pancreatic and non-small cell lung cancer. This acquisition, approved by N2OFF’s stockholders on September 25, 2025, involved the exchange of MitoCareX’s ordinary shares for N2OFF common stock, making MitoCareX a wholly-owned subsidiary. The merger is expected to enhance N2OFF’s market position by diversifying its portfolio into the biotech sector, with MitoCareX’s proprietary MITOLINE™ algorithm offering potential advancements in cancer therapeutics. The agreement also includes financial support for MitoCareX’s operations and entitles the sellers to a portion of N2OFF’s financing proceeds and milestone-based stock issuances.
More about N2OFF
N2OFF is a cleantech company primarily engaged in investing in solar energy assets across the European Union using the Ready to Build (RTB) business model. The company is also the lead investor in four solar projects in three different EU countries and holds a significant stake in Save Foods Ltd., an Israeli company focused on post-harvest treatments for fruits and vegetables.
Average Trading Volume: 323,741
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.81M
Find detailed analytics on NITO stock on TipRanks’ Stock Analysis page.